A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting the company on a path that could lead to its suspension from U. | Moderna is ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

Moderna’s study, involving 8,000 adults 50 and older, showed the new combo shot generated an immune response against COVID and most strains of flu compared to existing stand-alone shots.

Moderna could face suspension from Britain’s pharmaceutical trade body following a string of breaches of the regulatory code. The Covid vaccine maker is due to be audited by the Prescription ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue ...

CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut around $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news ...

Just over a month after leaving Moderna, Kate Cronin has a new healthcare leadership gig. Cronin, a 2020 MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic ...

Moderna is extending its cost savings program into 2027 and targeting a cash breakeven point sometime in 2028 as the larger U.S. vaccine market faces new uncertainties under the Trump administration.